It must be noted that glucagon-like peptide-1 receptor (GLP-1R) agonists, approved to treat obesity, elicit robust improvements in overweight, and provide cardioprotection in individuals at risk of or with pre-existing cardiovascular disease [102]. The gene discussed is GLP1R; the disease is obesity disorder.